Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 14/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552562 | 1.00 | GPR119 (0.47) | GPR119SCN9AKCNH2EPHA2ERBB2 | |
| SCHEMBL1552531 | 0.90 | GPR119 (0.46) | GPR119EPHA2ERBB2EPHB4 | |
| SCHEMBL1552527 | 0.90 | GPR119 (0.46) | GPR119EPHA2ERBB2EPHB4 | |
| SCHEMBL1552036 | 0.83 | EPHA2 (0.46) | GPR119KCNH2EPHA2ERBB2EPHB4 | |
| SCHEMBL1552035 | 0.83 | EPHA2 (0.46) | GPR119KCNH2EPHA2ERBB2EPHB4 | |
| SCHEMBL31076359 | 0.79 | EPHA2 (0.51) | EPHA2ERBB2EPHB4 | |
| SCHEMBL1553384 | 0.79 | SMPD1 (0.42) | EPHA2ERBB2EPHB4 | |
| SCHEMBL1553330 | 0.79 | SMPD1 (0.42) | EPHA2ERBB2EPHB4 | |
| SCHEMBL1552347 | 0.79 | NPC1 (0.49) | EPHA2ERBB2EPHB4 | |
| SCHEMBL1552349 | 0.79 | NPC1 (0.49) | EPHA2ERBB2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844026-B1 | MORPHOLINES AS 5HT2C AGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| CN-101107235-B | Morpholines as 5HT2C agonists | HOFFMANN LA ROCHE | 2011-03-16 | — | — | CN | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| CN-101107235-A | Morpholines as 5HT2C agonists | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | CN | disclosed |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HTR2C, HTR1A, HTR1B | GPR119 17/4885SCN9A 1785/4885KCNH2 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.